Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1279]

Rocbrutinib shows strong responses in resistant CLL, including BTKi- and...

Prof Jennifer Woyach - The Ohio State University, Columbus, USA

Rocbrutinib shows strong responses in resistant CLL, including BTKi- and venetoclax-exposed patients ( Prof Jennifer Woyach - The Ohio State University, Columbus, USA )

ESMO 2025: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2025: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Best practice in precision medicine for prostate cancer

Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich

Best practice in precision medicine for prostate cancer ( Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich )

Sacituzumab tirumotecan improves progression-free and overall survival in EGFR...

Dr Li Zhang - Sun Yat-sen University Cancer Center, Guangzhou, China

Sacituzumab tirumotecan improves progression-free and overall survival in EGFR-TKI resistant NSCLC ( Dr Li Zhang - Sun Yat-sen University Cancer Center, Guangzhou, China )

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients...

Dr Javier C Cortés - Hospital Ruber Internacional, Madrid Spain

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors ( Dr Javier C Cortés - Hospital Ruber Internacional, Madrid Spain )

177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher...

Dr Kim Nguyen Chi - BC Cancer, British Columbia, Canada

177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher PSA response with lower toxicity ( Dr Kim Nguyen Chi - BC Cancer, British Columbia, Canada )

Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2...

Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA

Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2-negative GC/GEJC/EAC ( Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA )

Non-clear cell renal cell carcinoma: Management of papillary RCC

Prof Camillo Porta and Prof Laurence Albiges

Non-clear cell renal cell carcinoma: Management of papillary RCC ( Prof Camillo Porta and Prof Laurence Albiges )

Treatment management of favourable risk and very favourable risk patients

Dr Guillermo de Velasco and Dr Marco Maruzzo

Treatment management of favourable risk and very favourable risk patients ( Dr Guillermo de Velasco and Dr Marco Maruzzo )

Understanding genetic aberrations in lung cancer treatment: NTRK, RET, NRG

Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA

Understanding genetic aberrations in lung cancer treatment: NTRK, RET, NRG ( Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA )

ASCO 2025: Developments in the treatment of soft tissue sarcoma

Dr Atif Hussein - Memorial Cancer Institute, Miami, USA

ASCO 2025: Developments in the treatment of soft tissue sarcoma ( Dr Atif Hussein - Memorial Cancer Institute, Miami, USA )

Florida Atlantic University and Memorial Cancer Institute collaboration

Dr Gregg B. Fields - Florida Atlantic University, Florida, USA

Florida Atlantic University and Memorial Cancer Institute collaboration ( Dr Gregg B. Fields - Florida Atlantic University, Florida, USA )

More from ecancer